Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Nov 3, 1999

Keywords

ClinConnect Summary

Leukocyte adhesion deficiency type I (LAD I) is a primary immunodeficiency disease resulting from mutations in the gene encoding CD18. Markedly reduced or absent expression of the leukocyte integrin component CD18 causes significant impairment in leukocyte mobilization to inflammatory sites. Clinically, patients have marked leukocytosis and recurrent infections involving soft tissues such as skin, the gastrointestinal tract and gingiva. Death due to infections in early infancy is common with the severe form of LAD I (CD18 expression less than 0.5%), but patients with the moderate phenotype ...

Gender

ALL

Eligibility criteria

• PARTICIPANT INCLUSION CRITERIA:
• • Leukocyte Adhesion Deficiency type I, as determined by flow cytometry showing less than 10% CD18 expression in association with typical signs of LAD I .
• • Weight adequate to permit the blood drawing requirements of the protocol, greater than 13 kg.
• • Patients should be without serious, ongoing, uncontrolled infections.
• Adequate hematopoietic, renal and hepatic function, defined as:
• • Absolute neutrophil count greater than or equal to 1500/microL;
• • Hemoglobin greater than or equal to 7g/dL (post transfusion or erythropoeitin);
• • Platelet count greater than or equal to 100,000/microL;
• • Creatinine less than or equal to 1.5 x upper limit of normal;
• • Bilirubin less than or equal to 1.5 x upper limit of normal;
• • AST/SGOT less than or equal to 2.5 x upper limit of normal;
• • ALT/SGPT less than or equal to 2.5 x upper limit of normal;
• • Calculated Creatinine Clearance greater than or equal to 60 mL/min.
• • Karnofsky Performance Status Index greater than or equal to 70.
• • Written signed informed consent.
• PARTICIPANT EXCLUSION CRITERIA:
• • HIV infection.
• • Active malignancy.
• • Symptomatic cardiac disease or ongoing treatment for same.
• • Pregnant or lactating women.
• • Surgery during the two weeks prior to the start of IFN-gamma dosing.
• • Concurrent use of systemic corticosteroids, except for physiologic replacement.
• • Exposure to any investigational drug within four weeks prior to the start of dosing.
• • Any other major illness which, in the investigator's judgement, may substantially increase the risk associated with the patients participation in this study.